Therapeutic advances in COVID-19

N Murakami, R Hayden, T Hills, H Al-Samkari… - Nature Reviews …, 2023‏ - nature.com
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2024‏ - academic.oup.com
There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …

Early remdesivir to prevent progression to severe Covid-19 in outpatients

RL Gottlieb, CE Vaca, R Paredes, J Mera… - … England Journal of …, 2022‏ - Mass Medical Soc
Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Accelerating antiviral drug discovery: lessons from COVID-19

A Von Delft, MD Hall, AD Kwong, LA Purcell… - Nature Reviews Drug …, 2023‏ - nature.com
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …

Structural biology of SARS-CoV-2: open the door for novel therapies

W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022‏ - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

LJ Stevens, AJ Pruijssers, HW Lee… - Science translational …, 2022‏ - science.org
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

BE Jones, PL Brown-Augsburger, KS Corbett… - Science translational …, 2021‏ - science.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …

Coronavirus biology and replication: implications for SARS-CoV-2

P V'kovski, A Kratzel, S Steiner, H Stalder… - Nature Reviews …, 2021‏ - nature.com
The SARS-CoV-2 pandemic and its unprecedented global societal and economic disruptive
impact has marked the third zoonotic introduction of a highly pathogenic coronavirus into the …

COVID-19: a global challenge with old history, epidemiology and progress so far

M Khan, SF Adil, HZ Alkhathlan, MN Tahir, S Saif… - Molecules, 2020‏ - mdpi.com
Humans have witnessed three deadly pandemics so far in the twenty-first century which are
associated with novel coronaviruses: SARS, Middle East respiratory syndrome (MERS), and …

COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment

A Parasher - Postgraduate medical journal, 2021‏ - academic.oup.com
Background The severe acute respiratory syndrome (SARS) coronavirus-2 is a novel
coronavirus belonging to the family Coronaviridae and is now known to be responsible for …